Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Poseida Therapeutics, Inc is a biotechnology business based in the US. Poseida Therapeutics shares (PSTX) are listed on the NASDAQ and all prices are listed in US Dollars. Poseida Therapeutics employs 208 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$8.45|
|52-week range||$7.63 - $15.79|
|50-day moving average||$9.05|
|200-day moving average||$9.32|
|Wall St. target price||$25.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||-14.39%|
|3 months (2021-04-29)||-12.07%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-34.65%|
|Return on equity TTM||-101.49%|
|Market capitalisation||$571.2 million|
TTM: trailing 12 months
There are currently 2.8 million Poseida Therapeutics shares held short by investors – that's known as Poseida Therapeutics's "short interest". This figure is 6.7% down from 3.0 million last month.
There are a few different ways that this level of interest in shorting Poseida Therapeutics shares can be evaluated.
Poseida Therapeutics's "short interest ratio" (SIR) is the quantity of Poseida Therapeutics shares currently shorted divided by the average quantity of Poseida Therapeutics shares traded daily (recently around 276323.58121331). Poseida Therapeutics's SIR currently stands at 10.22. In other words for every 100,000 Poseida Therapeutics shares traded daily on the market, roughly 10220 shares are currently held short.
However Poseida Therapeutics's short interest can also be evaluated against the total number of Poseida Therapeutics shares, or, against the total number of tradable Poseida Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Poseida Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Poseida Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0869% of the tradable shares (for every 100,000 tradable Poseida Therapeutics shares, roughly 87 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Poseida Therapeutics.
Find out more about how you can short Poseida Therapeutics stock.
We're not expecting Poseida Therapeutics to pay a dividend over the next 12 months.
Poseida Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. The company was incorporated in 2014 and is headquartered in San Diego, California. .
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.